[A22-44] Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146

Last updated 20.05.2022

Project no.:
A22-44

Commission:
Commission awarded on 12.04.2022 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express programmed cell death ligand 1 (PD-L1, combined positive score [CPS] ≥ 5)

Result of dossier assessment:

After addendum:

  • Oesophageal adenocarcinoma: hint of considerable added benefit.
  • Gastric or gastro-oesophageal junction adenocarcinoma: hint of considerable added benefit.
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2022-05-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form